On 7th March, the European Medicines Agency (EMA), an agency of the European Union, launched the Priority Medicines scheme (PRIME).
PRIME aims to enhance support for the development of new medicines which may offer a major advantage over existing treatments, or benefit patients with no existing treatment options. Through PRIME, the EMA will streamline evaluation so medicines can reach patients earlier.
MEP for South East England, Richard Ashworth, said: “The launch of the Priority Medicines scheme (PRIME) by the European Union is a welcome step towards finding a cure for thousands of UK patients suffering from untreatable conditions.”
“Those enduring the hardship of a rare cancer, Alzheimer’s disease or another form of dementia, could see earlier access to new treatments thanks to the ‘accelerated assessment’ for medicines under PRIME.”